The Role of Immune Modulation in the Carcinogenesis and Treatment of HPV-Associated Oropharyngeal Cancer
Human papillomavirus (HPV) is increasingly identified as a causative agent for oropharyngeal squamous cell carcinoma (OPSCC), often in relatively young patients lacking traditional carcinogenic risk factors such as tobacco and alcohol use. A growing body of literature has highlighted the importance of immune impairment in the pathogenesis of HPV-related premalignant and malignant lesions in the uterine cervix and, more recently, the oropharynx. This chapter will summarize current knowledge of the mechanisms that human papillomaviruses have evolved to evade the host immune system in the development of malignancy and will conclude with a discussion on preventive and therapeutic strategies that exploit these immune modulatory mechanisms.
KeywordsNatural Killer Cell Oropharyngeal Squamous Cell Carcinoma Tonsillar Crypt Immune Checkpoint Pathway
- Bauman JE, Gooding WE, Clump DA et al (2014) Phase I trial of cetuximab, intensity modulated radiotherapy (IMRT), and the anti-CTLA-4 monoclonal antibody (mAb) ipilimumab in previously untreated, locally advanced head and neck squamous cell carcinoma (PULA HNSCC). Abstracts from the annual meeting of the American Society of Clinical Oncology, Chicago, Illinois, 31 May–3 June, 2014Google Scholar
- Brun JL, Dalstein V, Leveque J et al (2011) Regression of high-grade cervical intraepithelial neoplasia with TG4001 targeted immunotherapy. Am J Obstet Gynecol 204:169.e1–8Google Scholar
- Clinical Trials Database (2014) National Cancer Institute, Bethesda. http://www.cancer.gov/clinicaltrials/search/view?cdrid=749477&version=HealthProfessional. Accessed 26 June 2014
- Ferris R (2013) PD-1 targeting in cancer immunotherapy. Cancer 119. doi: 10.1002/cncr.27832
- Tindle RW (2002) Immune evasion in human papillomavirus-associated cervical cancer. Cancer 2:1–7Google Scholar